HURA Form 4 reports acquisition/exercise transactions

MANUSO JAMES S J reported acquisition or exercise transactions in a Form 4 filing for HURA.

Accepted by SEC EDGAR 02/17/2026 - 04:17 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

MANUSO JAMES S J reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.

Insider Trade Summary

Grant/Award: 156,240 shares

Grant/Award 1 txn

Insider MANUSO JAMES S J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	156,240	$0.00	$0.00
Holding	Options (Right to Buy)	--	--	--

Holdings After Transaction: Options (Right to Buy) — 215,830 contracts for 59,590 underlying shares (Direct)

Holdings Before and After: Options (Right to Buy), 59,590 to 215,830 contracts (Direct)

Footnotes (2)

1. F1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
2. F2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TuHURA Biosciences (HURA) disclose about James Manuso on this Form 4?

TuHURA Biosciences disclosed that director James S. J. Manuso received a new stock option grant. He was awarded options to buy 156,240 shares at $1.29 per share, vesting over three years, under the company’s 2024 Equity Incentive Plan.

How many TuHURA Biosciences (HURA) options were granted to James Manuso and at what price?

James S. J. Manuso was granted 156,240 stock options of TuHURA Biosciences. These options have an exercise price of $1.29 per share and were issued as an annual grant under the 2024 Equity Incentive Plan, vesting in three equal annual installments.

What is the vesting schedule for James Manuso’s new TuHURA Biosciences (HURA) options?

The new options granted to James S. J. Manuso vest in three equal installments. One-third becomes exercisable on each of the first, second, and third anniversaries of February 12, 2026, aligning vesting with continued service over that three-year period.

When do James Manuso’s TuHURA Biosciences (HURA) option grants expire?

The new 156,240 options granted to James S. J. Manuso expire on February 12, 2036. He also holds an earlier annual grant of 59,590 options expiring on January 2, 2035, both reported as directly owned derivative securities linked to TuHURA common stock.

What earlier TuHURA Biosciences (HURA) option grant does James Manuso still hold?

James S. J. Manuso continues to hold a prior annual option grant for 59,590 shares of TuHURA common stock. These options carry a $4.11 exercise price, were originally granted on January 2, 2025, and expire on January 2, 2035, with vesting over three annual anniversaries.

Are James Manuso’s TuHURA Biosciences (HURA) options held directly or indirectly?

Both the new 156,240-option grant and the 59,590 existing options are reported as directly owned by James S. J. Manuso. The filing lists the ownership form as “D” for direct, with no footnote indicating holding through a separate entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MANUSO JAMES S J

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.29	02/12/2026(1)		A		156,240		(1)	02/12/2036	Common Stock	156,240	$0	156,240	D
Options (Right to Buy)	$4.11							(2)	01/02/2035	Common Stock	59,590		59,590	D

Explanation of Responses:

1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

	/s/ Dan Dearborn as Power of Attorney for James Manuso	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.